Phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics of XL880,a VEGFRR and MET kinase inhibitor, administered daily to patients with advanced malignancies [abstract]
Phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics of XL880,a VEGFRR and MET kinase inhibitor, administered daily to patients with advanced malignancies [abstract]. Proc AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. 2007; A-B248.